$ALLO
Allogene Therapeutics, Inc. Stock $allo

$allo Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000173728721000022 Filed on May 05, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$38.35M	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$16.36M	$15.64M
YoY Change	4.6%	19.75%
% of Gross Profit
Research & Development	$55.18M	$42.04M
YoY Change	31.26%	79.64%
% of Gross Profit
Depreciation & Amortization	$1.918M	$1.893M
YoY Change	1.32%	247.98%
% of Gross Profit
Operating Expenses	$71.55M	$57.68M
YoY Change	24.03%	58.2%
Operating Profit	-$33.20M	-$57.68M
YoY Change	-42.44%	58.2%
Interest Expense	$510.0K	$3.260M
YoY Change	-84.36%	-32.51%
% of Operating Profit
Other Income/Expense, Net	$186.0K	$3.203M
YoY Change	-94.19%	-33.62%
Pretax Income	-$33.02M	-$54.48M
YoY Change	-39.39%	72.21%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$33.02M	-$54.48M
YoY Change	-39.4%	72.48%
Net Earnings / Revenue	-86.1%
Basic Earnings Per Share	-$0.25
Diluted Earnings Per Share	-$0.25	-$500.0K
COMMON SHARES
Basic Shares Outstanding	132.2M shares	124.9M shares
Diluted Shares Outstanding	132.2M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$699.6M	$492.9M
YoY Change	41.93%	4.78%
Cash & Equivalents	$236.9M	$135.9M
Short-Term Investments	$462.7M	$357.0M
Other Short-Term Assets	$16.50M	$11.50M
YoY Change	43.48%	9.52%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$716.1M	$504.4M
YoY Change	41.96%	5.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$123.1M	$66.35M
YoY Change	85.6%	224.83%
Goodwill
YoY Change
Intangibles		$0.00
YoY Change		-100.0%
Long-Term Investments	$283.9M	$65.00M
YoY Change	336.77%	-69.71%
Other Assets	$6.275M	$4.675M
YoY Change	34.22%	982.18%
Total Long-Term Assets	$463.0M	$184.1M
YoY Change	151.47%	-32.5%
TOTAL ASSETS
Total Short-Term Assets	$716.1M	$504.4M
Total Long-Term Assets	$463.0M	$184.1M
Total Assets	$1.179B	$688.5M
YoY Change	71.24%	-8.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.88M	$7.199M
YoY Change	106.63%	-44.52%
Accrued Expenses	$39.70M	$19.60M
YoY Change	102.55%	37.06%
Deferred Revenue	$239.0K
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$54.85M	$26.82M
YoY Change	104.52%	-1.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.791M	$3.650M
YoY Change	-23.53%	-39.82%
Total Long-Term Liabilities	$2.791M	$3.650M
YoY Change	-23.53%	-39.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$54.85M	$26.82M
Total Long-Term Liabilities	$2.791M	$3.650M
Total Liabilities	$109.3M	$82.00M
YoY Change	33.24%	20.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$679.4M	-$450.6M
YoY Change	50.78%	85.35%
Common Stock	$1.749B	$1.056B
YoY Change	65.72%	14.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.070B	$606.5M
YoY Change
Total Liabilities & Shareholders Equity	$1.179B	$688.5M
YoY Change	71.24%	-8.12%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$33.02M	-$54.48M
YoY Change	-39.4%	72.48%
Depreciation, Depletion And Amortization	$1.918M	$1.893M
YoY Change	1.32%	247.98%
Cash From Operating Activities	-$49.33M	-$40.81M
YoY Change	20.88%	34.88%
INVESTING ACTIVITIES
Capital Expenditures	$6.461M	$12.25M
YoY Change	-47.27%	17.56%
Acquisitions
YoY Change
Other Investing Activities	$103.3M	-$2.750M
YoY Change	-3854.91%	-106.35%
Cash From Investing Activities	$96.80M	-$15.01M
YoY Change	-745.02%	-145.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$14.85M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$6.044M	$16.59M
YoY Change	-63.56%	2324.85%
NET CHANGE
Cash From Operating Activities	-$49.33M	-$40.81M
Cash From Investing Activities	$96.80M	-$15.01M
Cash From Financing Activities	$6.044M	$16.59M
Net Change In Cash	$53.51M	-$39.23M
YoY Change	-236.41%	-1283.05%
FREE CASH FLOW
Cash From Operating Activities	-$49.33M	-$40.81M
Capital Expenditures	$6.461M	$12.25M
Free Cash Flow	-$55.79M	-$53.06M
YoY Change	5.14%	30.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001737287
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001737287
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	allo:AccruedAndOtherLiabilitiesCurrent
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-38693
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	Allogene Therapeutics, Inc.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3562771
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	210 East Grand Avenue
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2021Q1	dei	City Area Code CityAreaCode	650
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	457-2700
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2021Q1	dei	Trading Symbol TradingSymbol	ALLO
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	141538421	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	236865000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	183351000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	462716000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	644559000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16480000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17220000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	716061000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	845130000	USD
CY2021Q1	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	39735000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	264573000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	204208000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	40189000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41295000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	123146000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	118840000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	9449000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	9449000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6275000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5169000	USD
CY2021Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	19351000	USD
CY2020Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	3738000	USD
CY2021Q1	us-gaap	Assets Assets	1179044000	USD
CY2020Q4	us-gaap	Assets Assets	1227829000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	14875000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10390000	USD
CY2020Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	44938000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	239000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	38992000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	54849000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94320000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51625000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50809000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2791000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3083000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	109265000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	148212000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141470075	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141470075	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	140474305	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	140474305	shares
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1725552000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-679358000	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	141000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	140000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1749097000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-646343000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-101000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	268000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	1069779000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1079617000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1179044000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1227829000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38345000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55183000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42042000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16363000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15641000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	71546000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	57683000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-33201000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-57683000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	511000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3261000	USD
CY2021Q1	us-gaap	Other Expenses OtherExpenses	325000	USD
CY2020Q1	us-gaap	Other Expenses OtherExpenses	58000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	186000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3203000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-33015000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-54480000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-369000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	465000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33384000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54015000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	132165014	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	108963522	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1079617000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4060000	USD
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	710000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16792000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1984000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-33015000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-369000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	1069779000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	629023000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	303000	USD
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	710000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14215000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1438000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14845000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-54480000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	465000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	606519000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-33015000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-54480000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	16792000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	14215000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	151000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	1918000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	1893000	USD
CY2021Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-1911000	USD
CY2020Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	207000	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	2007000	USD
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	718000	USD
CY2021Q1	allo	Income Loss From Cost Method Investment IncomeLossFromCostMethodInvestment	-325000	USD
CY2020Q1	allo	Income Loss From Cost Method Investment IncomeLossFromCostMethodInvestment	-64000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-740000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2552000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	799000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	57000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4152000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1044000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4314000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3913000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-38753000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-292000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-701000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-49328000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40809000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6461000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12253000	USD
CY2021Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	15938000	USD
CY2020Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	268249000	USD
CY2020Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	120261000	USD
CY2021Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	149052000	USD
CY2020Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	123015000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	96798000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15007000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4060000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	303000	USD
CY2021Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1984000	USD
CY2020Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1438000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6044000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16586000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	53514000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-39230000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	192800000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179425000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	246314000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140195000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8299000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4208000	USD
CY2021Q1	allo	Capitalized Software Costs Incurred Not Yet Paid CapitalizedSoftwareCostsIncurredNotYetPaid	277000	USD
CY2020Q1	allo	Capitalized Software Costs Incurred Not Yet Paid CapitalizedSoftwareCostsIncurredNotYetPaid	0	USD
CY2021Q1	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	966000	USD
CY2020Q1	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	1396000	USD
CY2021Q1	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-1111000	USD
CY2020Q1	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-532000	USD
CY2021Q1	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November 30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company’s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company's product candidates. The Company had cash and cash equivalents and investments of $964.2 million as of March 31, 2021. Since inception through March 31, 2021, the Company has incurred cumulative net losses of $679.4 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC). </span></div>The Company cannot at this time predict the specific extent, duration, or full impact that the ongoing COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If business conditions, financial markets and/or the overall economy are impacted for an extended period, the Company’s results may be adversely affected.
CY2021Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	964200000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-679400000	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	903575000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	400000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	59000	USD
CY2021Q1	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	903916000	USD
CY2021Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	176627000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	462716000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	264573000	USD
CY2021Q1	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	903916000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	950095000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	764000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	53000	USD
CY2020Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	950806000	USD
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	102039000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	644559000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	204208000	USD
CY2020Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	950806000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P3Y
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	5000000.0	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	137971000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	131748000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14825000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12908000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	123146000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	118840000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38300000	USD
CY2018Q3	allo	Area Of New Office Building AreaOfNewOfficeBuilding	68000	sqft
CY2018Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P127M
CY2018Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2021Q1	us-gaap	Tenant Improvements TenantImprovements	5000000.0	USD
CY2018Q4	allo	Area Of New Office Building AreaOfNewOfficeBuilding	14943	sqft
CY2018Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P124M
CY2018Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2018Q4	allo	Tenant Improvement Allowance TenantImprovementAllowance	800000	USD
CY2021Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	5200000	USD
CY2020Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	4300000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3061000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2974000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51625000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50809000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	54686000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	53783000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1862000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1868000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	327000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	210000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	2189000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	2078000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1000000.0	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	5044000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7917000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8168000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8430000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8509000	USD
CY2021Q1	allo	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	48143000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	86211000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	31200000	USD
CY2021Q1	allo	Tenant Improvement Allowance TenantImprovementAllowance	325000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	54686000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0840
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y2M19D
CY2020Q3	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P20Y
CY2020Q3	allo	Lessee Finance Lease Payment Upon Contract Termination LesseeFinanceLeasePaymentUponContractTermination	4300000	USD
CY2021Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	4100000	USD
CY2021Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	19400000	USD
CY2020Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	3700000	USD
CY2021Q1	allo	Number Of Shares As Percentage Of Common Shares Outstanding NumberOfSharesAsPercentageOfCommonSharesOutstanding	0.05
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17212410	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16792000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14215000	USD
CY2021Q1	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	2800000	USD
CY2020Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	2800000	USD
CY2021Q1	us-gaap	Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent	400000	USD
CY2020Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent	1100000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38300000	USD
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21900607	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29182402	shares

Files In Submission

Name	View Source	Status
0001737287-21-000022-index-headers.html	Edgar Link	pending
0001737287-21-000022-index.html	Edgar Link	pending
0001737287-21-000022.txt	Edgar Link	pending
0001737287-21-000022-xbrl.zip	Edgar Link	pending
allo-20210331.htm	Edgar Link	pending
allo-20210331.xsd	Edgar Link	pending
allo-20210331xex311.htm	Edgar Link	pending
allo-20210331xex312.htm	Edgar Link	pending
allo-20210331xex321.htm	Edgar Link	pending
allo-20210331_cal.xml	Edgar Link	unprocessable
allo-20210331_def.xml	Edgar Link	unprocessable
allo-20210331_htm.xml	Edgar Link	completed
allo-20210331_lab.xml	Edgar Link	unprocessable
allo-20210331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALLO
Allogene Therapeutics, Inc. Stock $allo

2021 Q1 Form 10-Q Financial Statement

#000173728721000022 Filed on May 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO Allogene Therapeutics, Inc. Stock $allo

2021 Q1 Form 10-Q Financial Statement

#000173728721000022 Filed on May 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO
Allogene Therapeutics, Inc. Stock $allo